EGFR and non-small cell lung carcinoma: It is currently indicated for the first-line treatment of patients with metastatic NSCLC whose tumors harbor del19 or L858R EGFR mutations and for metastatic squamous NSCLC progressing after platinum therapy (Boehringer Ingelheim Pharmaceuticals, 2016).